Logo Logo
Help
Contact
Switch Language to German

Miebach, Lisa; Wolfsgruber, Steffen; Polcher, Alexandra; Peters, Oliver; Menne, Felix; Luther, Katja; Incesoy, Enise; Priller, Josef; Spruth, Eike; Altenstein, Slawek; Buerger, Katharina; Catak, Cihan; Janowitz, Daniel; Perneczky, Robert; Utecht, Julia; Laske, Christoph; Buchmann, Martina; Schneider, Anja; Fliessbach, Klaus; Kalbhen, Pascal; Heneka, Michael T.; Brosseron, Frederic; Spottke, Annika; Roy, Nina; Teipel, Stefan J.; Kilimann, Ingo; Wiltfang, Jens; Bartels, Claudia; Duezel, Emrah; Dobisch, Laura; Metzger, Coraline; Meiberth, Dix; Ramirez, Alfredo; Jessen, Frank and Wagner, Michael (2019): Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. In: Alzheimers Research & Therapy, Vol. 11, 66

Full text not available from 'Open Access LMU'.

Abstract

BackgroundSubjective cognitive decline (SCD) has been proposed as a pre-MCI at-risk condition of Alzheimer's disease (AD). Current research is focusing on a refined assessment of specific SCD features associated with increased risk for AD, as proposed in the SCD-plus criteria. We developed a structured interview (SCD-I) for the assessment of these features and tested their relationship with AD biomarkers.MethodsWe analyzed data of 205 cognitively normal participants of the DELCODE study (mean age=68.9years;52% female) with available CSF AD biomarkers (A beta-42, p-Tau181, A beta-42/Tau ratio, total Tau). For each of five cognitive domains (including memory, language, attention, planning, others), a study physician asked participants about the following SCD-plus features: the presence of subjective decline, associated worries, onset of SCD, feeling of worse performance than others of the same age group, and informant confirmation. We compared AD biomarkers of subjects endorsing each of these questions with those who did not, controlling for age. SCD was also quantified by two summary scores: the number of fulfilled SCD-plus features, and the number of domains with experienced decline. Covariate-adjusted linear regression analyses were used to test whether these SCD scores predicted abnormality in AD biomarkers.ResultsLower A beta-42 levels were associated with a reported decline in memory and language abilities, and with the following SCD-plus features: onset of subjective decline within 5years, confirmation of cognitive decline by an informant, and decline-related worries. Furthermore, both quantitative SCD scores were associated with lower A beta 42 and lower A beta 42/Tau ratio, but not with total Tau or p-Tau181.ConclusionsFindings support the usefulness of a criterion-based interview approach to assess and quantify SCD in the context of AD and validate the current SCD-plus features as predictors of AD pathology. While some features seem to be more closely associated with AD biomarkers than others, aggregated scores over several SCD-plus features or SCD domains may be the best predictors of AD pathology.

Actions (login required)

View Item View Item